FZD2 and hepatocellular carcinoma: In HCC, the upregulation of ligands (Wnt1, Wnt3A, etc.)and FZD receptors (FZD2 and FZD7), along with frequent CTNNB1 mutations, is linked to early tumorigenesis, elevated risk of recurrence, and worse clinical outcomes.